A Phase 2 Study of Stem-Cell-Mobilization in Subjects With Diabetic Neuropathy Receiving SB-509.
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2017
At a glance
- Drugs SB 509 (Primary)
- Indications Diabetic neuropathies
- Focus Pharmacodynamics
- Sponsors Sangamo BioSciences
- 03 Mar 2010 Actual number of patients (23) added as reported by ClinicalTrials.gov.
- 03 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Sep 2008 Status changed from recruiting to active, no longer recruiting according to CLinialtrials.gov record.